GO
Loading...

Actavis Inc

More

  • LONDON, Nov 14- Pfizer appears unlikely to make a fresh bid for AstraZeneca in 12 days time, when an enforced cooling-off period ends, and the U.S. drugmaker is now weighing other less risky targets. People with direct knowledge of the situation said Pfizer has been reviewing different takeover scenarios with a U.S. investment bank ahead of Nov. 26, when it is allowed...

  • Nov 12- Merger talks between Allergan Inc and white knight Actavis Plc are focused on narrowing a gap of about $3 billion between what has been offered and what is wanted, Bloomberg reported on Wednesday. Actavis is willing to pay around $200 per share, or $60 billion, while Allergan wants more than $210 per share, Bloomberg said. The amended laws now include a...

  • Nov 12- Actavis Plc is in talks to buy Allergan Inc for at least $60 billion in a deal that could culminate this month, Bloomberg reported, citing sources familiar with the matter. The two companies are trying to narrow a gap of about $3 billion between what Actavis wants to pay and what Allergan is asking for, Bloomberg reported. Allergan, which is trying to fend off a...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman wrote to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be Actavis, to fend...

  • BOSTON, Nov 7- Valeant Pharmaceuticals International Inc can pay "substantially" more for Allergan Inc and should get a fair shot at buying it, William Ackman, the Botox maker's biggest shareholder, said on Friday. Ackman said this in a letter to Allergan's board the day after the company said it was discussing a merger with another company, widely reported to be...

  • The two companies were close to inking a deal, but Botox maker Allergan balked after its due diligence raised questions over inventory levels, the people said, requesting anonymity because the negotiations were confidential. Earlier on Thursday, Allergan said it was in discussions with another party that a source familiar with the situation identified as...

  • Nov 5- The top executive of Actavis Inc, which sources say is pursuing a "white knight" acquisition of Allergan Inc, made a case Wednesday for doing a deal, saying the drug company could continue to grow earnings and manage its debt load. "If there was an opportunity, I think we've demonstrated as a team that if it was the right strategic opportunity with strong...

  • Nov 3- Botox maker Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management, which owns nearly a 10 percent stake in Allergan, made an offer now worth $55 billion for Allergan at the end of April.

  • Nov 3- Allergan Inc, which is fending off an acquisition by Valeant Pharmaceuticals Inc, said on Monday that it had been approached by another party regarding a potential transaction. Valeant and Pershing Square Capital Management made an offer, now worth $55 billion, for Allergan at the end of April. Pershing Square owns nearly a 10 percent stake in Allergan.

  • Early movers: AAPL, AZN, SHPG, FB, MSFT, DB & more Tuesday, 23 Sep 2014 | 7:41 AM ET
    A trader works on the floor of the New York Stock Exchange in New York.

    Some of the names on the move ahead of the open.

  • Early movers: HSY, SHLD, BX, BA, LMNT, BABA & more Tuesday, 16 Sep 2014 | 7:35 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer: Get this company on your radar, now! Monday, 4 Aug 2014 | 6:33 PM ET

    Ahead of earnings, Jim Cramer thinks you should know about this stock and the potential it presents.

  • Cooperman: Buy these stocks now Wednesday, 16 Jul 2014 | 12:22 PM ET
    Omega Advisors CEO Leon G. Cooperman speaks at the CNBC Institutional Investor Delivering Alpha Conference in New York.

    Billionaire investor Leon Cooperman gave 12 stock recommendations at the Delivering Alpha conference Wednesday.

  • Allergan to shareholders: Ignore Pershing Square Friday, 11 Jul 2014 | 6:31 PM ET
    A vial of Allergan’s Botox is arranged next to boxes for a photograph at a doctor's office in Manhattan Beach, Calif.

    Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.

  • Early movers: NFLX, WYNN, APP & more Tuesday, 1 Jul 2014 | 7:56 AM ET

    Some of the names on the move ahead of the open.

  • Why rivals are jealous of Pfizer's AstraZeneca deal Thursday, 1 May 2014 | 7:15 AM ET
    U.S. drugmaker Pfizer proposed buying AstraZeneca for about 58.8 billion pounds ($98.7 billion) in what would rank as the industry's biggest-ever takeover, surpassing Pfizer's $64 billion purchase of Wyeth in 2009.

    As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.

  • Focus is on Fed, but this may move markets instead Wednesday, 30 Apr 2014 | 9:30 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Wall Street has its eye on the Federal Reserve's meeting, but a slew of data is likely to have more influence on stocks Wednesday.

  • Early movers: CMCSA, PFE, AZN, GE & more Monday, 28 Apr 2014 | 8:02 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer’s game plan: Stock strategies amid earnings Friday, 25 Apr 2014 | 6:07 PM ET

    With the market in the thick of earnings, next week promises to be an eventful five days for investors. Are you ready? Cramer sure is.

  • Pfizer-AstraZeneca deal? Not as crazy as it sounds Monday, 21 Apr 2014 | 6:24 PM ET
    Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc.

    There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.